Center Laboratories, Inc.

Notice of Annual Shareholders' Meeting 2026

I. The 2026 Annual Shareholders' Meeting will be held on Friday, June 12, 2026, at 9:00 a.m. The meeting will take place in Room 447, 4th Floor, Building E, No. 19-11 Sanchong Road, Nangang District, Taipei City (Nangang Software Incubator). The shareholders' registration for this meeting will begin at 8:30 a.m., and the registration desk will be located at the meeting venue.

Meeting Agenda:

(I) Report Items:

1. 2025 Business Report.
2. 2025 Audit Committee's Review Report.
3. 2025 The Distribution of Employees' Compensation and Directors' Remuneration Report.
4. 2025 Directors' Remuneration Report .
5. 2025 Material Related Party Transactions Report .
6. Report on the Status of Private Placement.
7. Report on the Status of Issuance of the Company's 8th Domestic Unsecured Convertible Corporate Bonds and the 9th Domestic Unsecured Convertible Corporate Bonds.

(II) Ratification Items :

1. Ratification of the Company's 2025 Business Report and Financial Statements.
2. Ratification of the Company's 2025 Earnings Distribution Proposal.

(III) Discussion Items:

1. Proposal for the Amendment to the Company's "Articles of Incorporation".
2. Proposal to Release Non-Compete Restrictions for Directors.
3. Proposal for the issuance of new common shares for capital increase out of earnings.
4. Proposal for the issuance of new common shares by private placement in cash.

(IV) Extemporary Motions.

II. If the agenda for this shareholders' meeting includes any proposals that are required to be specified under Article 172 of the Company Act, please visit the

Market Observation Post System (MOPS) at https://mops.twse.com.tw, and navigate to “Single Company” > “Electronic Documents Download” > “Annual Reports and Shareholders' Meeting Information.” Enter the company code (or abbreviation) and the relevant year to access the “Reference Materials for Shareholders’ Meeting Proposals” or the “Agenda Handbook and Supplemental Materials.”

III. The proposal for the distribution of 2025 earnings, as approved by the Board of Directors, is as follows:

1. Cash dividends: It is proposed to appropriate NT$1,326,853,719 from earnings as cash dividends (NT$1.75 per share), rounded down to the nearest dollar, and the aggregate of such fractional amounts shall be recognized as the Company’s other income.
2. Stock dividends: (1) It is proposed to appropriate NT$379,101,070 from earnings for a capital increase through the issuance of 37,910,107 new shares, with 50 bonus shares to be distributed without consideration for every 1,000 shares held. For fractional shares of less than one share, shareholders may, within 5 days from the book closure date, apply to the Company’s stock transfer agent to combine such fractional shares into whole shares. Any remaining fractional shares shall be paid in cash at par value, rounded down to the nearest dollar, and it is proposed that the shareholders’ meeting authorize the Chairman to arrange for subscription by designated persons at par value. For shareholders receiving shares through book-entry transfer, any cash payment for fractional shares of less than one share shall be used as the handling fee for the book-entry transfer. (2) After this capital increase is approved by the shareholders’ meeting and by the competent authority, it is proposed that the shareholders’ meeting authorize the Board of Directors to separately determine the record date for the capital increase.
3. If, subsequently, the number of the Company’s issued or outstanding shares changes due to the Company’s repurchase or transfer of treasury shares, the exercise of employee stock options by the Company’s employees, applications by holders of convertible corporate bonds to convert such bonds into common shares, private placement cash capital increase through the issuance of common shares, or other factors under applicable laws and regulations, and adjustment of the stock dividend ratio or cash dividend ratio for shareholders is therefore required, it is proposed that the shareholders’ meeting authorize the Chairman to handle the matter with full authority.

IV. **Explanation of matters relating to the private placement of common shares through cash capital increase (please refer to Appendix 1).**

V. Pursuant to Article 165 of the Company Act, the registration of share transfer shall be suspended from April 14, 2026 to June 12, 2026.

VI. In addition to the public announcement, we hereby send this letter together with one attendance card and one proxy form for the shareholders' meeting. We kindly ask that you review the enclosed documents and attend the meeting if your schedule permits. For shareholders who attend the meeting in person, please fill out the **second copy of the attendance card, affix your seal or signature**, and bring it directly to the venue for registration on the day of the meeting. There is no need to return it by mail. If a proxy attends, please fill in the **second copy of the proxy form and affix a seal or signature** and submit it to the shareholder services agent of the Company, Capital Securities Corp., Stock Transfer Agency Department, five days before the meeting. The stock transfer agent will then prepare the attendance card and send it to your proxy, who shall present it to attend the shareholders' meeting.

VII. If any shareholder solicits proxies, the Company will, before May 12, 2026, prepare a summary statement of proxy solicitation information and disclose it on the website of the Securities and Futures Institute. Investors who wish to make inquiries may directly visit https://free.sfi.org.tw and go to "Free Inquiry of Proxy Solicitation Information" and enter the relevant search criteria.

VIII. The institution responsible for the tabulation and verification of proxy forms for this shareholders' meeting is the Stock Transfer Agency Department of Capital Securities Corp.

IX. Shareholders may exercise their voting rights electronically for this shareholders' meeting during the period from May 13, 2026 to June 9, 2026. Please log in to the "Shareholder e-Service" webpage of Taiwan Depository & Clearing Corporation and follow the relevant instructions to vote [URL: https://stockservices.tdcc.com.tw].

Sincerely,

To Our Shareholders.

The Board of Directors of Center Laboratories, Inc.

【Appendix 1】

Explanation of Matters Relating to the Private Placement of Common Shares through Cash Capital Increase:

1. To strengthen working capital, repay borrowings, and invest in the biotechnology industry, and after taking into consideration timeliness, convenience, and issuance costs, the Company proposes to conduct a private placement of common shares through a cash capital increase.
2. The total number of shares to be issued under this private placement shall not exceed 30,000,000 shares and is expected to be carried out in two tranches within one year from the date of resolution by the shareholders' meeting.
3. In accordance with Article 43-6 of the Securities and Exchange Act and the "Directions for Public Companies Conducting Private Placements of Securities," the relevant details of the private placement are as follows:
   (1) Basis for and reasonableness of the pricing:
   The reference price for the private placement shall be determined based on the higher of the following two calculations:
      A. The simple average closing price of the Company's common shares for either 1, 3, or 5 business days prior to the pricing date, adjusted for stock dividends, cash dividends, and capital reduction.
      B. The simple average closing price of the Company's common shares for the 30 business days prior to the pricing date, adjusted for ex-rights, ex-dividend, and capital reduction.

   The private placement price shall not be less than 80% of the reference price. The pricing methodology complies with applicable laws and regulations and is considered reasonable. The actual pricing date and subscription price, within the range approved by the shareholders' meeting, are proposed to be authorized to the Board of Directors for determination based on negotiations with specific persons and prevailing market conditions.

   (2) Selection of specific persons, purpose, necessity, and expected benefits:
   The offerees will be limited to specific persons in accordance with Article 43-6 of the Securities and Exchange Act and related regulations, and will be selected primarily from strategic investors. The Board of Directors is authorized to identify and negotiate with such specific persons. To support the Company's future development, improve its financial structure, and enhance profitability, it

is necessary to introduce strategic partners that can contribute to the Company's operations. Through their experience, technology, and expertise, such partners are expected to enhance operating performance and support the Company's long-term growth.

(3) Necessity of the private placement:

A. Reasons for not adopting a public offering: Considering the timeliness, convenience, and cost of issuance, a private placement provides a more efficient means of raising capital. In addition, the statutory restriction on transfer within three years helps maintain a stable long-term relationship with strategic investors.

B. Number of shares to be issued: No more than 30,000,000 ordinary shares, and the shares will be issued twice within one year respectively from the date of the resolution of the shareholders' meeting. No more than 15,000,000 shares for the first issuance, and no more than 15,000,000 shares for the second issuance.

C. Purpose of private placement: The two private placements are used to replenish working capitals, repay borrowings and invest in the biotechnology industry.

D. Expected benefits: The expected benefits from the two private placements are to strengthen financial structure and improve operating efficiency as well as corporate competitiveness.

4. Rights and obligations of the privately placed shares:

The rights and obligations of the privately placed common shares shall be the same as those of the Company's existing common shares. However, in accordance with the Securities and Exchange Act, such shares may not be transferred within three years from the date of delivery, except to permitted transferees as specified by law. After the expiration of the three-year period, the Board of Directors is authorized to apply to the competent authority for public issuance and listing (or OTC trading) in accordance with applicable regulations.

5. The main terms of the private placement plan, including the actual issue price, number of shares, issuance conditions, pricing date, capital increase record date, project items, total amount to be raised, expected schedule, and anticipated benefits, as well as all other related matters, will be determined by the Board of Directors based on market conditions. In the event of any regulatory changes, instructions from competent authorities, or adjustments required due to operational or market conditions, the Board of Directors is authorized to make such amendments

accordingly.

6. To facilitate the private placement, the Chairman, or a person designated by the Chairman, is authorized to execute and negotiate all agreements and documents related to the private placement and to handle all related matters on behalf of the Company.
7. Impact of the private placement on the Company's managerial control: The Company's managerial control is stable; therefore, the private placement is not expected to have a material impact on the Company's managerial control.
8. Any matters not addressed herein shall be handled by the Board of Directors in accordance with applicable laws and regulations.
9. Information related to this private placement, as required under Article 43-6 of the Securities and Exchange Act, is available on the Market Observation Post System (MOPS) at https://mops.twse.com.tw. Please navigate to "Special Sections" > "Investor Area" > "Private Placement Section." Relevant information can also be found on the Company's website at https://www.centerlab.com.tw.